Search Results

, palpable, biopsy-proven early-stage breast cancer were randomized to receive either surgery (lumpectomy and axillary lymph node dissection or modified radical mastectomy) followed by 4 cycles of doxorubicin (60 mg/m 2 ) and cyclophosphamide (600 mg/m 2

coding for vulvar cancer regarding whether pelvic lymph nodes are defined as regional or nonregional, and therefore we omitted distinction between inguinal and pelvic lymph node dissection in the setting of regional lymph node evaluation. Treatment

subsequently underwent right modified radical mastectomy with axillary lymph node dissection. Pathology results showed multifocal residual disease measuring up to 16.5 cm, with >10 additional satellite tumors and skin involvement. Among resected axillary lymph

right breast cancer diagnosed 3 years before presentation, which was treated with mastectomy, sentinel lymph node dissection, and adjuvant cyclophosphamide and doxorubicin (4 cycles); the patient subsequently underwent maintenance therapy with oral

-chemotherapy retroperitoneal lymph node dissection . Br J Cancer 1999 ; 80 : 249 – 255 . 55. Howell SJ Shalet SM . Spermatogenesis after cancer treatment: damage and recovery . J Natl Cancer Inst Monogr 2005 ; 34 : 12 – 17 . 56. Brydoy M Fossa SD

extrafascial radical prostatectomy, and right pelvic lymph node dissection revealed Gleason grade 3+4=7 adenocarcinoma that occupied 5% of a 20-gram prostate. Gleason grade was overestimated due to prostate biopsy undersampling, which occurs rarely. 9

with retroperitoneal lymph node dissection only? Which patients with stage II and III disease will need to undergo resection of residual masses after chemotherapy?” he continued. Dr. Gilligan explained that the 8th edition has made some changes, but

cancer, including radical prostatectomy with or without pelvic lymph node dissection, external-beam radiation therapy (EBRT) with 4 to 6 months of androgen deprivation therapy (ADT), or combination EBRT with a brachytherapy (BT) boost with or without ADT

omental caking. CA-125 serum tumor marker at time of presentation was elevated at 1,155 kU/L (normal range, <35 kU/L). The patient underwent primary surgery with radical hysterectomy, bilateral salpingo-oophorectomy, lymph node dissection, and removal of

-oophorectomy and pelvic and periaortic lymph node dissection for stage III uterine carcinosarcoma in March 2016. She completed 6 cycles of carboplatin and paclitaxel therapy and 4,860 cGy of RT to the pelvic and aortic nodes. She later developed subcutaneous